Name of this trial: Destiny-BTC
What type of cancer is this for? Biliary Tract Cancer
Who is this trial for? First line for locally advanced or metastatic HER2 expressing biliary tract cancer
What biomarkers are involved? HER2 positive (expressing)
What is the National Clinical Trial #? NCT06467357
Brief summary of this trial: Phase 3 trial of trastuzumab deruxtecan and rilvegostomig Vs standard of care treatment. This is an open-label design with randomization into 1 of 2 arms.
Need to know: May have had prior treatment in the perioperative and/or adjuvant setting, but no treatment in the locally advanced or metastatic space.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]